Form 4: Celldex Therapeutics SVP, Chief Medical Officer, Diane C. Young, Reports Acquisition of Incentive Stock Options
SEC Form 4 Filing
Diane C. Young, SVP, Chief Medical Officer of Celldex Therapeutics, reports the acquisition of incentive stock options.
Summary
- Diane C. Young, SVP, Chief Medical Officer of Celldex Therapeutics, filed a Form 4 on June 17, 2024, reporting a transaction on June 13, 2024.
- Young acquired 72,000 incentive stock options with an exercise price of $36.43.
- These options vest 25% on June 13, 2025, and the remainder vest quarterly over the subsequent 12 quarters.
- The options expire on June 13, 2034.
- Following the reported transaction, Young directly owns 72,000 derivative securities.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it is a standard insider transaction report. The acquisition of stock options can be seen as a positive sign, but it's a routine part of executive compensation.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and actions regarding their company's stock.
Stakeholder Impact
- The acquisition of stock options by a key executive could be perceived positively by shareholders, indicating confidence in the company's future performance.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of transaction: acquisition of incentive stock options |
| 06/13/2025 | 25% of the options vest |
| 06/13/2034 | Expiration date of the options |
| 06/17/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.